Retinal Disease

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Retinal Disease

MalaCards integrated aliases for Retinal Disease:

Name: Retinal Disease 12 15
Retinal Diseases 43 15 71
Retinal Disorders 42


External Ids:

Disease Ontology 12 DOID:5679
ICD9CM 34 362.9
MeSH 43 D012164
SNOMED-CT 67 29555009 35426003
ICD10 32 H35.8 H35.9 H36
UMLS 71 C0035309

Summaries for Retinal Disease

MedlinePlus : 42 The retina is a layer of tissue in the back of your eye that senses light and sends images to your brain. In the center of this nerve tissue is the macula. It provides the sharp, central vision needed for reading, driving and seeing fine detail. Retinal disorders affect this vital tissue. They can affect your vision, and some can be serious enough to cause blindness. Examples are Macular degeneration - a disease that destroys your sharp, central vision Diabetic eye disease Retinal detachment - a medical emergency, when the retina is pulled away from the back of the eye Retinoblastoma - cancer of the retina. It is most common in young children. Macular pucker - scar tissue on the macula Macular hole - a small break in the macula that usually happens to people over 60 Floaters - cobwebs or specks in your field of vision NIH: National Eye Institute

MalaCards based summary : Retinal Disease, also known as retinal diseases, is related to cone dystrophy and retinoschisis 1, x-linked, juvenile, and has symptoms including eye manifestations An important gene associated with Retinal Disease is PRPH2 (Peripherin 2), and among its related pathways/superpathways are Phototransduction and Visual Cycle in Retinal Rods. The drugs Methylcobalamin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and endothelial, and related phenotypes are nervous system and cardiovascular system

Disease Ontology : 12 An eye disease that is located in the retina.

Wikipedia : 74 The retina is the innermost, light-sensitive layer of tissue of the eye of most vertebrates and some... more...

Related Diseases for Retinal Disease

Diseases in the Retinal Disease family:

Inherited Retinal Disorder Rare Retinal Disorder

Diseases related to Retinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 481)
# Related Disease Score Top Affiliating Genes
1 cone dystrophy 33.0 USH2A RPGR RPE65 RHO PRPH2 PDE6B
2 retinoschisis 1, x-linked, juvenile 33.0 RPGR RPE65 RHO NR2E3 CRX CRB1
3 retinal degeneration 33.0 USH2A RPGR RPE65 RHO PRPH2 PDE6B
4 retinitis pigmentosa 33.0 USH2A RPGR RPE65 RHO PRPH2 PRPF31
5 enhanced s-cone syndrome 33.0 RPGR RPE65 RHO NR2E3 CRX AIPL1
6 leber congenital amaurosis 32.9 USH2A RPGR RPE65 RHO PRPH2 PRPF31
7 stargardt disease 32.9 USH2A RPGR RPE65 RHO PRPH2 PRPF31
8 choroidal dystrophy, central areolar, 1 32.5 RPE65 PRPH2 GUCY2D CRX AIPL1 ABCA4
9 senior-loken syndrome 1 32.5 USH2A RPGR RPE65 GUCY2D CRX CRB1
10 macular dystrophy, vitelliform, 3 32.4 PRPH2 BEST1
11 night blindness, congenital stationary, autosomal dominant 1 32.4 RHO CACNA1F
12 cone-rod dystrophy, x-linked, 3 32.3 RPGR CACNA1F
13 retinitis 32.1 USH2A RPGR RPE65 RHO PRPH2 PRPF31
14 yemenite deaf-blind hypopigmentation syndrome 32.0 USH2A RPGR RPE65 RHO MYO7A GUCY2D
15 usher syndrome, type i 32.0 USH2A RPGR RPE65 RHO PDE6B MYO7A
16 macular degeneration, age-related, 1 32.0 USH2A RPGR RPE65 RHO PRPH2 PDE6B
17 leber congenital amaurosis 2 31.9 RPE65 RHO MYO7A GUCY2D CRX CRB1
18 pattern dystrophy 31.9 RHO PRPH2 CRX
19 night blindness, congenital stationary, type 1a 31.9 RHO CACNA1F
20 macular retinal edema 31.7 RHO CRB1 BEST1 ALB
21 night blindness 31.5 USH2A RPGR RPE65 RHO PRPH2 PDE6B
22 retinal vascular disease 31.5 RHO ALB AIPL1
23 usher syndrome, type iiia 31.4 USH2A RPE65 PRPF31 PDE6B MYO7A CRB1
24 cone-rod dystrophy 2 31.4 USH2A RPGR RPE65 RHO PRPH2 PDE6B
25 congenital stationary night blindness 31.4 USH2A RPGR RPE65 RHO PRPH2 PRPF31
26 eye disease 31.3 USH2A RPGR RPE65 RHO PRPH2 PRPF31
27 leber congenital amaurosis 6 31.3 GUCY2D CRB1 CEP290 AIPL1
28 usher syndrome 31.3 USH2A RPGR RPE65 RHO PRPH2 PRPF31
29 inherited retinal disorder 31.3 USH2A RPGR RPE65 PRPH2 PRPF31 PDE6B
30 peripheral retinal degeneration 31.3 RPGR RHO PRPH2 PRPF31 ABCA4
31 leber congenital amaurosis 16 31.3 GUCY2D CRB1 AIPL1
32 leber congenital amaurosis 11 31.3 GUCY2D CRB1 AIPL1
33 leber congenital amaurosis 12 31.3 RPE65 GUCY2D AIPL1
34 leber congenital amaurosis 4 31.3 RPE65 PRPH2 GUCY2D CRX CRB1 CEP290
35 leber congenital amaurosis 7 31.3 GUCY2D CRX CRB1 AIPL1
36 central serous chorioretinopathy 31.3 CFH ARMS2
37 leber congenital amaurosis 8 31.3 GUCY2D CRB1 AIPL1
38 choroideremia 31.3 USH2A RPGR RPE65 ABCA4
39 leber congenital amaurosis 9 31.3 RPE65 GUCY2D CRX CRB1 CEP290 AIPL1
40 leber congenital amaurosis 3 31.3 RPE65 GUCY2D CRX CRB1 CEP290 AIPL1
41 achromatopsia 31.2 USH2A RPGR RPE65 RHO PRPH2 PDE6B
42 basal laminar drusen 31.2 PRPH2 CFH BEST1 ARMS2 ABCA4
43 doyne honeycomb retinal dystrophy 31.2 PRPH2 CFH BEST1 ARMS2 ABCA4
44 retinitis pigmentosa-deafness syndrome 31.2 USH2A MYO7A
45 retinitis pigmentosa 50 31.2 RPGR PRPH2 BEST1
46 scotoma 31.2 RPGR RPE65 RHO PRPH2 GUCY2D ABCA4
47 macular dystrophy, concentric annular 31.2 CRX ABCA4
48 retinitis pigmentosa 1 31.2 RHO PRPH2 CRX
49 retinitis pigmentosa 34 31.2 RPGR PRPF31 CRX
50 retinitis pigmentosa 40 31.2 RPGR PRPF31 PDE6B

Graphical network of the top 20 diseases related to Retinal Disease:

Diseases related to Retinal Disease

Symptoms & Phenotypes for Retinal Disease

UMLS symptoms related to Retinal Disease:

eye manifestations

MGI Mouse Phenotypes related to Retinal Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.06 ABCA4 AIPL1 CACNA1F CEP290 CFH CRB1
2 cardiovascular system MP:0005385 9.96 ABCA4 ALB CEP290 CFH CRB1 CRX
3 pigmentation MP:0001186 9.77 ABCA4 BEST1 CEP290 CFH CRB1 CRX
4 vision/eye MP:0005391 9.58 ABCA4 AIPL1 BEST1 CACNA1F CEP290 CFH

Drugs & Therapeutics for Retinal Disease

Drugs for Retinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 409)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
leucovorin Approved Phase 4 58-05-9 6006 143
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
Sodium citrate Approved, Investigational Phase 4 68-04-2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Bevacizumab Approved, Investigational Phase 4 216974-75-3
Dipivefrin Approved Phase 4 52365-63-6 3105
Benserazide Approved, Investigational Phase 4 322-35-0
Levodopa Approved Phase 4 59-92-7 6047
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
17 Grape Approved Phase 4
Verteporfin Approved, Investigational Phase 4 129497-78-5
Simvastatin Approved Phase 4 79902-63-9 54454
Fenofibrate Approved Phase 4 49562-28-9 3339
Fluorouracil Approved Phase 4 51-21-8 3385
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
Tesamorelin Approved, Investigational Phase 4 218949-48-5
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
Cobalamin Experimental Phase 4 13408-78-1 6857388
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
30 Vitamin B 12 Phase 4
31 Vitamin B12 Phase 4
32 Vitamin B 6 Phase 4
33 Ketorolac Tromethamine Phase 4
34 (T,G)-A-L Phase 4
Glatiramer Acetate Phase 4 147245-92-9 3081884
36 Cardiac Glycosides Phase 4
37 Glycoside Hydrolase Inhibitors Phase 4
38 Vardenafil Dihydrochloride Phase 4
39 Sildenafil Citrate Phase 4 171599-83-0
40 Citrate Phase 4
41 Phosphodiesterase Inhibitors Phase 4
42 Phosphodiesterase 5 Inhibitors Phase 4
43 Antineoplastic Agents, Immunological Phase 4
44 Benserazide, levodopa drug combination Phase 4
45 Calcium, Dietary Phase 4
46 Isophane Insulin, Human Phase 4
47 Isophane insulin, beef Phase 4
48 Insulin, Isophane Phase 4
49 Endothelial Growth Factors Phase 4
50 Mitogens Phase 4

Interventional clinical trials:

(show top 50) (show all 672)
# Name Status NCT ID Phase Drugs
1 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
2 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
3 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
4 CPAP Application at Delivery Room at Very Low Birth Weight Infants Unknown status NCT01024361 Phase 4
5 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
6 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
7 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
8 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
9 A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
10 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
11 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
12 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
13 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
14 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
15 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
16 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
17 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
18 Effect of Levodopa on Human Multifocal Electroretinogram Completed NCT00812760 Phase 4 levodopa
19 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
20 Evaluation of Diabetic Retinopathy Progression in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Completed NCT00174824 Phase 4 Insulin glargine
21 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
22 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment. A UK, 18-month, Prospective, Open-label, Multicentre, Single-arm, Phase IIIb Study With 12-month Primary Endpoint, Assessing the Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Oedema. Completed NCT01257815 Phase 4 Ranibizumab
23 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
24 DECREASING THE NEED FOR MECHANICAL VENTILATION AFTER RETINOPATHY OF PREMATURITY SURGERY: Sedation vs General Anesthesia Completed NCT01955135 Phase 4 Ketamine;Sevoflurane;propofol
25 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
26 Sucrose and Non Nutritive Suck as Analgesia for Babies Undergoing Retinopathy of Prematurity Screening; a Randomised Placebo Controlled Trial Completed NCT00921544 Phase 4
27 Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Diabetic Patients With Retinopathy. A Randomized Controlled Trial. Completed NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
28 An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18) Completed NCT01580020 Phase 4 Dexamethasone
29 Diabetic Macula Oedema. A Prospective Randomised Study Comparing the Detailed Functional and Anatomical Changes of Repeated Pan Anti-VEGF Therapy With Ranibizumab Versus Conventional Macular Laser Therapy. Completed NCT01223612 Phase 4 Ranibizumab
30 A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With (Best-Corrected Distance Visual Acuity) BCVA Below 2/10 and/or Second Affected Eye Completed NCT01986907 Phase 4 ranibizumab
31 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
32 A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy Completed NCT03962296 Phase 4 Vitis vinifera extract;Calcium Dobesilate;Placebo
33 Comparison of the Vascular Endothelial Growth Factor Serum Concentrations After Intravitreal Use of Bevacizumab or Ranibizumab as a Treatment for Type 1 Retinopathy of Prematurity Completed NCT03148132 Phase 4 Bevacizumab Injection;Ranibizumab Ophthalmic
34 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
35 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
36 A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC) Completed NCT01797861 Phase 4
37 Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography Completed NCT03246152 Phase 4 Bevacizumab
38 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V Completed NCT00563121 Phase 4
39 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V. Completed NCT00500396 Phase 4
40 A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes Recruiting NCT03439345 Phase 4 Fenofibrate 145 mg;Placebo Oral Tablet
41 Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab Recruiting NCT02559180 Phase 4 aflibercept
42 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Recruiting NCT03506750 Phase 4 IVC
43 Effect of Continuous Positive Airway Pressure on the Progression of Vascular Retinal Disease in Patients With Sleep Apnea and Non-proliferative Diabetic Retinopathy. A Randomized Clinical Trial Active, not recruiting NCT02874313 Phase 4 Pharmacological treatment
44 A Phase IV Randomised Clinical Trial of Laser Therapy for Peripheral Retinal Ischaemia Combined With Intravitreal Aflibercept (Eylea®) Versus Intravitreal Aflibercept Monotherapy for Diabetic Macular Oedema Active, not recruiting NCT02432547 Phase 4 Aflibercept
45 Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME (RMSM ICOD STUDY) Not yet recruiting NCT04038125 Phase 4 Ozurdex Drug Implant Product
46 Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients Not yet recruiting NCT04140201 Phase 4 Simvastatin 40mg;Fenofibrate 200mg;Omega 3 fatty acid
47 Outpatient Performed Pterygium Surgery Study Not yet recruiting NCT03037736 Phase 4 5-Fluorouracil;Bevacizumab;Normal saline
48 A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes Terminated NCT01591902 Phase 4 Tesamorelin;Placebo-Control
49 A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients. Unknown status NCT00908778 Phase 3 Vitreosolve;Vitreosolve
50 Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy Unknown status NCT00407108 Phase 3

Search NIH Clinical Center for Retinal Disease

Cochrane evidence based reviews: retinal diseases

Genetic Tests for Retinal Disease

Anatomical Context for Retinal Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Retinal Disease:


MalaCards organs/tissues related to Retinal Disease:

Retina, Eye, Endothelial, Testes, Brain, Bone, Bone Marrow

Publications for Retinal Disease

Articles related to Retinal Disease:

(show top 50) (show all 4904)
# Title Authors PMID Year
Spontaneous rupture of the eyeball due to choroidal metastasis of gastric carcinoma: A case report. 42
31577766 2019
Cumulative evidence for association of sepsis and retinopathy of prematurity. 42
31626109 2019
Bilateral proliferative retinopathy and ischemic optic neuropathy in a patient with atypical hemolytic-uremic syndrome: A case report. 42
31574834 2019
Beneficial effects of saffron (Crocus sativus L.) in ocular pathologies, particularly neurodegenerative retinal diseases. 61
31997799 2020
Retinal Vascular Signs and Cerebrovascular Diseases. 61
31977663 2020
The Schlager mouse as a model of altered retinal phenotype. 61
31571663 2020
Preface of Special Issue "Molecular Therapies for Inherited Retinal Diseases". 61
32033431 2020
[Retinal laser treatment-avoiding mistakes]. 61
32002621 2020
Antioxidant Role of PRGF on RPE Cells after Blue Light Insult as a Therapy for Neurodegenerative Diseases. 61
32033116 2020
Prevalence of and factors related with abnormal fundoscopic findings among the elderly population in a rural community in South Korea. 61
32026733 2020
Single-Cell Transcriptomic Comparison of Human Fetal Retina, hPSC-Derived Retinal Organoids, and Long-Term Retinal Cultures. 61
32023475 2020
Commentary: Artificial intelligence and smartphone fundus photography - Are we at the cusp of revolutionary changes in retinal disease detection? 61
31957736 2020
Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases. 61
31964843 2020
Prevalence of mutations in inherited retinal diseases: A comparison between the United States and India. 61
31816670 2020
[Fundus Autofluorescence Imaging: Clinical Application and Diagnostic Relevance]. 61
32016932 2020
Cell types and cell circuits in primate retina. 61
32032773 2020
Müller cells derived neurotrophin-3 inhibits hypoxia-induced photoreceptor apoptosis via the TrkC/ERK pathway. 61
31768729 2020
Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based Prediction. 61
31876425 2020
Expanding the phenotypic spectrum in RDH12-associated retinal disease. 61
32014858 2020
Novel mutation in CTNNB1 causes familial exudative vitreoretinopathy (FEVR) and microcephaly: case report and review of the literature. 61
32039639 2020
Cones in ageing and harsh environments: the neural economy hypothesis. 61
32017191 2020
Is there a relationship between dopamine and rhegmatogenous retinal detachment? 61
31552904 2020
32036367 2020
Sterculic Acid: The Mechanisms of Action beyond Stearoyl-CoA Desaturase Inhibition and Therapeutic Opportunities in Human Diseases. 61
31936134 2020
Connexin Hemichannel Block Using Orally Delivered Tonabersat Improves Outcomes in Animal Models of Retinal Disease. 61
31637594 2020
Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. 61
32001821 2020
Mitochondrial Defects Drive Degenerative Retinal Diseases. 61
31771932 2020
Multifocal intraocular lenses and retinal diseases. 61
31955239 2020
AOCT-NET: a convolutional network automated classification of multiclass retinal diseases using spectral-domain optical coherence tomography images. 61
31728935 2020
Light deprivation reduces the severity of experimental diabetic retinopathy. 61
31978605 2020
Gene Therapy Approaches to a Rare Retinal Disease: Choroideremia. 61
32031510 2020
Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina. 61
31672582 2020
Clinical and preclinical therapeutic outcome metrics for USH2A-related disease. 61
31998945 2020
Telemedicine and Pediatric Retinal Disease. 61
31855895 2020
Ablation of Immunoproteasome β5i Subunit Suppresses Hypertensive Retinopathy by Blocking ATRAP Degradation in Mice. 61
31636038 2020
Curcumin as a Therapeutic Option in Retinal Diseases. 61
31935797 2020
[Purtscher-like retinopathy associated with adult onset still disease: Case report and review of the literature]. 61
31983549 2020
Crumbs proteins regulate layered retinal vascular development required for vision. 61
31718797 2020
Inhibiting microRNA-144 potentiates Nrf2-dependent antioxidant signaling in RPE and protects against oxidative stress-induced outer retinal degeneration. 61
31590045 2020
Familial autosomal recessive bestrophinopathy: identification of a novel variant in BEST1 gene and the specific metabolomic profile. 61
31969119 2020
Automated diagnosis of diabetic retinopathy using clinical biomarkers, optical coherence tomography (OCT), and OCT angiography. 61
31982407 2020
Elucidating the mechanism of action of alpha-1-antitrypsin using retinal pigment epithelium cells exposed to high glucose. Potential use in diabetic retinopathy. 61
32032388 2020
Ultra-widefield retinal imaging: an update on recent advances. 61
32010879 2020
Systemic Administration of an Apelin Receptor Agonist Prevents NMDA-Induced Loss of Retinal Neuronal Cells in Mice. 61
31894462 2020
Comparison of Retinal Layer Thickness in Eyes with Resolved Diabetic Macular Edema Receiving Ranibizumab with Normal Eyes. 61
31747663 2020
31922497 2020
Automated classification of normal and Stargardt disease optical coherence tomography images using deep learning. 61
31981283 2020
Vertically integrated photo junction-field-effect transistor pixels for retinal prosthesis. 61
32010499 2020
A short period of dark-adaptation is sufficient to generate light-induced photoreceptor degeneration in pigmented zebrafish. 61
31789762 2020
Non-invasive molecular tracking method that measures ocular drug distribution in non-human primates. 61
31925329 2020

Variations for Retinal Disease

Expression for Retinal Disease

Search GEO for disease gene expression data for Retinal Disease.

Pathways for Retinal Disease

GO Terms for Retinal Disease

Cellular components related to Retinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 photoreceptor disc membrane GO:0097381 9.46 RHO PDE6B GUCY2D ABCA4
2 photoreceptor connecting cilium GO:0032391 9.43 USH2A MYO7A CEP290
3 photoreceptor inner segment GO:0001917 9.43 USH2A RHO MYO7A CRB1 ARMS2 AIPL1
4 photoreceptor outer segment GO:0001750 9.17 RPGR RHO PRPH2 MYO7A GUCY2D CACNA1F

Biological processes related to Retinal Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 response to stimulus GO:0050896 9.73 USH2A RPGR RPE65 RHO PDE6B NR2E3
2 retina development in camera-type eye GO:0060041 9.72 RPE65 RHO PRPH2 PDE6B NR2E3
3 retina homeostasis GO:0001895 9.71 RPE65 ARMS2 ALB AIPL1
4 retinoid metabolic process GO:0001523 9.7 RPE65 RHO ABCA4
5 photoreceptor cell maintenance GO:0045494 9.67 USH2A RHO ABCA4
6 regulation of rhodopsin mediated signaling pathway GO:0022400 9.67 RHO PDE6B GUCY2D AIPL1
7 detection of light stimulus involved in visual perception GO:0050908 9.63 RPE65 CACNA1F BEST1
8 sensory perception of light stimulus GO:0050953 9.61 USH2A RHO MYO7A
9 eye photoreceptor cell development GO:0042462 9.56 NR2E3 MYO7A CRB1 CEP290
10 rhodopsin mediated signaling pathway GO:0016056 9.54 RHO PDE6B
11 inner ear receptor cell differentiation GO:0060113 9.51 USH2A MYO7A
12 detection of light stimulus GO:0009583 9.48 RHO PDE6B
13 visual perception GO:0007601 9.47 USH2A RPGR RPE65 RHO PRPH2 PDE6B
14 phototransduction, visible light GO:0007603 9.46 RHO PDE6B AIPL1 ABCA4

Sources for Retinal Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....